In the past, the ADCS has had an active and successful minority recruitment core. In this submission we have expanded the function of the recruitment core to improve recruitment to all protocols and to evaluate recruitment efforts at the site level as well as across all sites.
The specific aims of the recruitment core are as follows: 1. Identify a full range of recruitment and retention activities, including both successful previously tried and newly proposed. 2. Review protocols with Project Directors to reduce barriers to recruitment. Aspects of the protocol to be reviewed include subject eligibility, study procedures, and schedule of events. The goal of the review will be to avoid unnecessary restrictions, and to minimize subject burden while maintaining scientific rigor. 3. Support and train site staff in recruitment and retention efforts. While the sites have been chosen for their expertise in evaluation and treatment of cognitive deficits and dementia as well as their commitment to conduct clinical trials, many are less familiar with communication techniques that can maximize recruitment. This mandatory training will provide an opportunity to introduce the techniques and methods and provide a dialogue for specific needs. The trial sites will be evaluated continually throughout the trial and lags in recruitment will lead to additional contact from the trial PI and the recruitment core leader, and a site-specific remedial program will be developed, implemented and monitored for success. 4. Maximize minority participation. We will continue our efforts to insure that our sites provide maximum opportunity for participation by minority populations. We will include training at the sites. In addition, we will continue our efforts to bring on selected sites which primarily serve minority populations.
Despite the long history by the NIH to ensure and enhance representation of ethnic minorities in biomedical research endeavors - significant disparities remain. The impact of the ongoing disparity is particularly negative when a disease is prevalent in minority populations. Moreover, clinical research results are must reflect the community at large. ADCS is committed to engaging in recruitment strategies as we strive to streamline and improve minority participation in all ADCS trials.
|Rentz, Dorene M; Dekhtyar, Maria; Sherman, Julia et al. (2016) The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis 3:8-12|
|Graff-Radford, Jonathan; Madhavan, Malini; Vemuri, Prashanthi et al. (2016) Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimers Dement 12:391-8|
|Johnson, Keith A; Schultz, Aaron; Betensky, Rebecca A et al. (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79:110-9|
|Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2016) Post Hoc Analyses of ApoE Genotype-Defined Subgroups in ClinicalÂ Trials. J Alzheimers Dis 50:1205-15|
|Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61|
|Raman, Mekala R; Schwarz, Christopher G; Murray, Melissa E et al. (2016) An MRI-Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease. J Neuroimaging 26:264-8|
|Gauthier, Serge; Feldman, Howard H; Schneider, Lon S et al. (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388:2873-2884|
|Le, Michelle H; Weissmiller, April M; Monte, Louise et al. (2016) Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport. PLoS One 11:e0147250|
|Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2016) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord :|
|Zhang, Cheng; Kuo, Ching-Chang; Moghadam, Setareh H et al. (2016) Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. Alzheimers Dement 12:527-37|
Showing the most recent 10 out of 402 publications